Scared Australian investors miss out on big biotech returns, page-4

  1. sirrakoski
    139 Posts.
    clock Created with Sketch.
    24/09/15
    18:16
    Post #: 16054864
    I expect Clinuvel's revenue to ramp up over the next 12 months. Drug approved in Europe for orphan indication and blockbuster potential on other indications including vitiligo.

    CUV 'new' substantial shareholder announcement yesterday. Phase 11 results due soon on vitiligo and Type C meeting with FDA this month
    Last edited by sirrakoski: 24/09/15
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.